Molecular breast imaging -- or MBI -- found 10 out of 13 tumors. Mammograms detected only three. Mammograms gave false alarms in about 9 percent of patients, compared to only 7 percent with MBI.
The Susan G. Komen for the Cure Foundation and Bristol-Myers Squibb, which makes the imaging agent used in the study, paid for the work.
The next test will be to see how MBI stacks up against MRI.